Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

dc.contributor.authorColombo, Nicoletta
dc.contributor.authorDubot, Coraline
dc.contributor.authorLorusso, Domenica
dc.contributor.authorCaceres, M. Valeria
dc.contributor.authorHasegawa, Kosei
dc.contributor.authorShapira-Frommer, Ronnie
dc.contributor.authorTewari, Krishnansu S.
dc.date.accessioned2025-05-10T15:21:54Z
dc.date.issued2022
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstract[No abstract available]
dc.identifier.doi10.1097/01.ogx.0000805152.09501.f1
dc.identifier.endpage31
dc.identifier.issn0029-7828
dc.identifier.issue1
dc.identifier.scopus2-s2.0-85123362104
dc.identifier.scopusqualityQ2
dc.identifier.startpage30
dc.identifier.urihttps://doi.org/10.1097/01.ogx.0000805152.09501.f1
dc.identifier.urihttps://hdl.handle.net/20.500.14730/6221
dc.identifier.volume77
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherLippincott Williams and Wilkins
dc.relation.ispartofObstetrical and Gynecological Survey
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_Scopus_20250302
dc.subjectantineoplastic metal complex; bevacizumab; carboplatin; cisplatin; paclitaxel; pembrolizumab; placebo; programmed death 1 ligand 1; adult; cancer chemotherapy; cancer patient; cancer radiotherapy; cancer recurrence; cancer survival; controlled study; double blind procedure; drug efficacy; drug safety; febrile neutropenia; female; follow up; human; intention to treat analysis; major clinical study; metastasis; multiple cycle treatment; Note; outcome assessment; overall survival; phase 3 clinical trial; progression free survival; protein expression; randomized controlled trial; superiority trial; treatment duration; tumor cell; urinary tract infection; uterine cervix cancer; young adult
dc.titlePembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
dc.typeNote

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
6221
Boyut:
684.73 KB
Biçim:
Adobe Portable Document Format